The Global Arteriovenous Fistula Devices Market size is expected to reach $521.9 million by 2030, rising at a market growth of 6.9% CAGR during the forecast period.
AVF procedures and equipment are in demand as a result of a considerable increase in renal disease cases in the Asia Pacific region. Therefore, the Asia Pacific region acquired $72.1 million revenue in the market in 2022. This development is explained by the rising incidence of ESRD and the number of people needing hemodialysis therapy. Additionally, the accessibility of these treatments has been facilitated by investments in cutting-edge medical technologies, such as AVF devices, and expanding healthcare infrastructure. Along with the existence of major market competitors and R&D efforts, the emphasis on improving patient outcomes as well as healthcare quality also contributes to the expansion of the market in this region. Some of the factors impacting the market are Increase in the demand for cutting-edge treatment techniques, growing prevalence of end-stage renal disease (ESRD), and numerous complications with AVF surgeries.
This market is anticipated to grow throughout the anticipated time frame as companies create novel treatment options such as antiangiogenic therapy, photodynamic therapy, and other sclerotherapy techniques. Players are motivated to develop cutting-edge treatment technologies since the ideal type of therapy for full recovery in a straightforward manner is still being developed. Early research findings are available, and minimally invasive novel system manufacturing techniques are being investigated. Additionally, many therapies in the research pipeline and upbeat government policies would increase demand for arteriovenous fistula devices throughout the projected period. Due to their long-term advantages as well as lower complication rates than alternative access methods, AVF devices are a favored vascular access option in response to the increased prevalence of chronic renal illnesses and ESRD. Each year, chronic kidney disease (CKD) causes thousands of people to pass away too soon and significantly lowers their quality of life. Hence, the increasing prevalence of ESRD will significantly augment the market's growth.
However, long surgical wait periods for the construction of AVFs and varied primary failure rates, which are AVFs that are never usable or fail within the initial three months, are two of the numerous obstacles to their usage. Between 20 and 70 percent of primary attempts fail. Needles are also necessary to reach the AV fistula for dialysis, which makes it an invasive procedure. Therefore, the market's growth would be constrained by the absence of successful therapies in treating the underlying causes of arteriovenous fistula.
The COVID-19 pandemic put a strain on the world's healthcare system. During the pandemic, a worldwide strategy to maintain the healthcare system was essential. Due to the severity of kidney disease, many governments allowed for its treatment even during the pandemic. However, the COVID-19 pandemic saw a rise in the number of dialysis-access thromboses as well as failed thrombectomies. This discrepancy was brought on by a delay in the patients' access maintenance operations. Therefore, the pandemic had a negative impact on the market.
On the basis of end-use, the market is classified into hospitals, ambulatory surgical centers, and dialysis centers. The ambulatory surgical centers (ASCs) segment witnessed a considerable growth rate in the market in 2022. These facilities offer outpatient surgical services, like AVF procedures, which are more practical and affordable than hospitalization. ASCs have become a feasible option for carrying out these procedures because of the increase in demand for AVF production and monitoring. As they provide high-quality care at a lesser cost than hospitals, ASCs are in line with the move toward value-based healthcare as well as cost containment.
Based on type, the market is characterized into AVF creation devices, AVF monitoring devices, and AVF maintenance devices. The AVF creation devices segment garnered the highest revenue share in the market in 2022. Greater demand for AVF procedures has been generated by the rising prevalence of ESRD as well as the rising number of people requiring dialysis treatment. By facilitating efficient vascular access, boosting patient care, and promoting quality of life, AVF creation devices are essential in supplying the growing need for dialysis treatment. The segment’s expansion is being fueled by the introduction of cutting-edge products by major companies that speed up the AVF process.
The AVF creation devices segment is further subdivided into surgical instruments, vascular grafts, angioplasty balloons, and others. The surgical instruments segment acquired the largest revenue share in the market in 2022. Depending on the instrument's nature and functioning, an arteriovenous fistula surgical tool set may be built of German, Japanese, or local steel. Making a fully effective blood-transporting mechanism requires the use of the AV fistula surgical equipment set. Scalpels, tissue forceps, scissors, needle holders, self-retaining retractors, bulldog clamps, vessel loops, and any other preferred surgical clamps are needed during surgery.
The AVF monitoring devices segment is fragmented into doppler ultrasound, pressure monitoring systems, and others. The Doppler ultrasound segment witnessed the maximum revenue share in the market in 2022. When performing vessel mapping, Doppler ultrasound is used to assess the blood vessels that the surgeon might employ to create the AV fistula. An image of an organ's structure can be obtained with ultrasound by using a device called a transducer to bounce safe, harmless sound waves off of the organ. The process is carried out in a medical professional's office, an outpatient facility, or a hospital by a properly trained technician.
The AVF maintenance devices segment is classified into central venous catheters, stents, and others. The central venous catheters segment procured the highest revenue share in the market in 2022. While patients wait for an arteriovenous fistula to be placed and develop, central venous catheters (CVCs) are routinely utilized for hemodialysis (HD) vascular access. CVCs are now a crucial adjuvant in keeping patients on HD. The internal jugular as well as femoral veins are the best places to implant catheters, while the subclavian vein is regarded as the third option.
| Report Attribute | Details |
|---|---|
| Market size value in 2022 | USD 309.2 Million |
| Market size forecast in 2030 | USD 521.9 Million |
| Base Year | 2022 |
| Historical Period | 2019 to 2021 |
| Forecast Period | 2023 to 2030 |
| Revenue Growth Rate | CAGR of 6.9% from 2023 to 2030 |
| Number of Pages | 345 |
| Number of Table | 540 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Type, End-use, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment garnered the maximum revenue share in the market in 2022. AVF devices are essential for supplying vascular access for hemodialysis, which is necessary given the high prevalence of kidney disease in North America. The expansion of the regional marketplace is attributed to the increasing demand for AVF treatments and the focus on patient outcomes. Furthermore, the market for arteriovenous fistula devices is expanding in North America due to the presence of significant manufacturers and advantageous healthcare regulations.
Free Valuable Insights: Global Arteriovenous Fistula Devices Market size to reach USD 521.9 Million by 2030
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Becton, Dickinson and Company, Teleflex, Inc., Fresenius Medical Care AG & Co. KGaA. (Fresenius SE & Co. KGaA), B. Braun Melsungen AG, Poly Medicure Ltd., Asahi Kasei Corporation, Laminate Medical Technologies Ltd., Cook Medical, Inc. (Cook Group), and Boston Scientific Corporation.
By End-use
By Type
By Geography
This Market size is expected to reach $521.9 million by 2030.
Growing prevalence of end-stage renal disease (ESRD) are driving the Market in coming years, however, Numerous complications with AVF surgeries restraints the growth of the Market.
Medtronic PLC, Becton, Dickinson and Company, Teleflex, Inc., Fresenius Medical Care AG & Co. KGaA. (Fresenius SE & Co. KGaA), B. Braun Melsungen AG, Poly Medicure Ltd., Asahi Kasei Corporation, Laminate Medical Technologies Ltd., Cook Medical, Inc. (Cook Group), and Boston Scientific Corporation.
The expected CAGR of this Market is 6.9% from 2023 to 2030.
The Hospitals segment is leading the Market by End-use in 2022; thereby, achieving a market value of $276.2 million by 2030.
The North America region dominated the Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $204.9 million by 2030.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 